樂
樂觀
樂觀 · 25%KYTX
$4.24
情境價格
$5.630
+0.385 (+6.83%)收盤時
Loading chart…
- 最高
- 5.670
- 開盤
- 5.240
- 成交量加權均價
- 5.49
- 成交量
- 916.66K
- 市值
- —
- 最低
- 5.160
- 成交金額
- 5.03M
- 企業價值/稅息折舊攤銷前利潤（TTM）
- 0.00
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
AI 分析 of Kyverna Therapeutics Inc (KYTX)
賣出Kyverna Therapeutics Inc is not a good buy right now due to significant financial losses and negative momentum. The current price is $5.39, and the stock has a 1-year change of -30.99%. Furthermore, the RSI is at 27.395, indicating oversold conditions, but the overall trend remains negative. The company reported a net loss of $39,728,000 in Q1 2026, and the forward P/E is at 0, suggesting no earnings growth in the near term. The main risk is the ongoing investigations into corporate governance breaches, which could further impact investor confidence.
估值指標
Kyverna Therapeutics Inc（KYTX）目前預期本益比為 0.00，5 年平均預期本益比為 -2.51。
Alphio AI 對 KYTX 的價格情境
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。
持有 KYTX 的大戶
事件時間軸
資訊
9.010-23NewsfilterMiv-cel Shows Promising Efficacy in Progressive Multiple Sclerosis
7.010-22PRnewswireInvestigation into Kyverna Therapeutics' Corporate Governance Breaches
- 7.010-22Newsfilter
Investigation into Kyverna Therapeutics' Fiduciary Duties
- 9.010-21Newsfilter
Miv-cel Achieves Breakthrough Efficacy in Stiff Person Syndrome
9.009-24stocktwitsKyverna's Miv-cel Shows Promising Results in Stiff Person Syndrome Study
KYTX 常見問題 —— 由 Alphio AI 解答
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).
Kyverna Therapeutics Inc is not a good buy right now due to significant financial losses and negative momentum. The current price is $5.39, and the stock has a 1-year change of -30.99%. Furthermore, the RSI is at 27.395, indicating oversold conditions, but the overall trend remains negative. The company reported a net loss of $39,728,000 in Q1 2026, and the forward P/E is at 0, suggesting no earnings growth in the near term. The main risk is the ongoing investigations into corporate governance breaches, which could further impact investor confidence.
社群
更多 ↗
$KYTX Swarmer's miv-cel shows positive results in stiff person syndrome and gMG Kyverna Therapeutics announced positive one-year topline data from KYSA-8, its registrational trial of miv-cel - mivocabtagene autoleucel, KYV-101 - in patients with stiff person syndrome or SPS, and positive topline longer-term follow-up data from the Phase 2 portion of KYSA-6, its registrational trial in patients with generalized myasthenia gravis, or gMG. Data from both trials will be shared at upcoming medical meetings. The primary endpoint and all key secondary endpoints were achieved with statistical significance in KYSA-8. The topline one-year durability data further strengthen the positive results. Miv-cel continued to be well-tolerated. Longer-term Phase 2 follow-up in gMG demonstrate robust and durable effects sustained for up to 1.5 years, with majority of patients maintaining MSE. Kyverna intends to include the one-year data in its rolling BLA submission, on track to be completed in Q4. The full data set will be presented at MS Toronto, October 21-23, in Toronto. All 7 patients achieved clinically meaningful improvement in MG-ADL and QMG, co-primary endpoints of the ongoing Phase 3 portion. All 7 patients remained free of immunotherapies for MG. Miv-cel continued to be well-tolerated. The Phase 3 portion of the KYSA-6 trial is ongoing, with enrollment expected to be completed in mid-2027.
展開本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。